1. Home
  2. AGBK vs CGEM Comparison

AGBK vs CGEM Comparison

Compare AGBK & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AGBK

AGI Inc Class A Common Shares

N/A

Current Price

$6.25

Market Cap

1.0B

Sector

Finance

ML Signal

N/A

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$19.85

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGBK
CGEM
Founded
1999
2016
Country
Brazil
United States
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.1B
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
AGBK
CGEM
Price
$6.25
$19.85
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
8
Target Price
$17.20
$30.13
AVG Volume (30 Days)
405.3K
528.4K
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$235.22
$5.20
P/E Ratio
$46.19
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.07
$5.68
52 Week High
$12.21
$19.94

Technical Indicators

Market Signals
Indicator
AGBK
CGEM
Relative Strength Index (RSI) 35.48 68.97
Support Level N/A $11.87
Resistance Level $7.54 N/A
Average True Range (ATR) 0.37 1.11
MACD -0.09 0.26
Stochastic Oscillator 13.64 83.94

Price Performance

Historical Comparison
AGBK
CGEM

About AGBK AGI Inc Class A Common Shares

AGI Inc is a technology-powered provider of specialized financial services in Brazil. It empowers clients to access their social security benefits, severance fund benefits, and public or private sector payrolls through secured lending solutions and complementary banking, credit and insurance products tailored as per client needs. The company has one operating segment related to the banking business. The Bank provides a standardized set of financial products and services exclusively to individuals, mainly focused on credit, including digital accounts, cards, payroll and personal loans, and insurance offered through partners.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: